Clinical Trial

Codexis to Participate in Enzymatic Synthesis Presentations at RNA Leaders Annual Meeting

REDWOOD CITY, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced…

1 year ago

Koa Health Launches Proactive Mental Health Solution For Employers to Unify and Simplify the Continuum of Care

The clinically validated, unified platform aims to move beyond just therapy to deliver easy-to-use, real-time prevention, treatment, and maintenance for…

1 year ago

Clario publishes third annual ESG Report, reaffirms commitment to ethical AI, workforce investment, and sustainability targets

Clario's third annual ESG report for the calendar year 2023 highlights advancements in responsible artificial intelligence (AI), employee program investments,…

1 year ago

Zomedica Announces Key Educational Presentations at Fetch dvm360 Veterinary Conference

Leading veterinary experts to present at the Fetch dvm360 Veterinary Conference in Kansas City, August 23-25, 2024 ANN ARBOR, MI…

1 year ago

AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen Additional commentary published discussing the potential…

1 year ago

Entera Bio to Participate in Upcoming Investor and Scientific Conferences

JERUSALEM, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the…

1 year ago

Avadel Pharmaceuticals Announces Publication in Clinical Therapeutics of Data Highlighting Weight Loss in People with Narcolepsy Treated with LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension

DUBLIN, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform…

1 year ago

Opus Genetics Receives Rare Pediatric Disease Designation from the U.S. FDA for Ocular Gene Therapy OPGx-LCA5 to Treat Rare Inherited Retinal Disease LCA5

Priority Review Voucher would be issued upon approval of OPGx-LCA5RESEARCH TRIANGLE PARK, N.C., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Opus…

1 year ago

LAVA Reports Second Quarter 2024 Financial Results and Business Update

Continued progress in Phase 1/2a dose escalation for LAVA-1207, including the monotherapy arm, now enrolling in dose level 12, and…

1 year ago

Agilisium Recognized as a Leader in Everest Group Life Sciences Digital Services for Mid-Market Enterprises PEAK Matrix®Report

LOS ANGELES, Aug. 19, 2024 /PRNewswire/ -- Agilisium, a premier digital innovations partner for Life Sciences companies, today announced that it…

1 year ago